BioSpace News Archive

Drug Development

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Oral presentation confirms patients achieved clinically meaningful nadir serum asparaginase activity throughout the course of Rylaze treatment with intramuscular dosing regimen administered 25/25/50 mg/m 2 on Monday/Wednesday/Friday.

June 7, 2022
·
11 min read
Mindset Pharma to Participate in Upcoming Conferences in June 2022

Mindset Pharma Inc. today announced that management will participate in three upcoming conferences Grizzle Psychedelics Con 2022 to be held virtually on Wednesday, June 8, 2022.

June 7, 2022
·
3 min read
Business

Singular Genomics and Olink Collaborate to Enable Olink® Explore on the G4 Max Read™ Sequencing Kits

Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) and Singular Genomics Systems, Inc. (Nasdaq: OMIC) today announced a collaboration to enable use of the Olink® Explore high-throughput proteomics platform with the Max Read kits on the Singular Genomics G4™ Sequencing Platform.

June 7, 2022
·
5 min read
Pharm Country

Aquestive Therapeutics to Participate in JMP Securities Life Sciences Conference

Aquestive Therapeutics, Inc. announced that the management team will participate in the JMP Securities Life Sciences Conference from June 15th to June 16th.

June 7, 2022
·
6 min read
Deals

Kindbody Acquires Leading Genomics Company Phosphorus Labs, Will Add Genetic Testing and Carrier Screening to Its End-to-End Care Delivery Model

Kindbody, a leading fertility and family-building benefits provider for employers offering comprehensive virtual and in-person care, announced today the acquisition of Phosphorus Labs, a leading preventative genomics company.

June 7, 2022
·
3 min read
Pharm Country

Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases

Round led by Northpond Ventures with participation from new investors Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors.

June 7, 2022
·
4 min read
Drug Development

Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI).

June 7, 2022
·
7 min read
BioMidwest

AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial

Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia.

June 7, 2022
·
3 min read
Drug Development

Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Nascent Biotech, Inc. is pleased to announce the completion of the Third cohort in dosing patients for its Phase I trial for Brain Cancer.

June 7, 2022
·
2 min read
Business

Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of industry veteran Andrew S. Sandler, M.D., as its Chief Medical Officer.

June 7, 2022
·
5 min read